Skip to main content

Table 5 NAT evaluations with the CT and MRI measurements between the groups (PD/SD, CR/PR) based on the RECIST 1.1 guidelines

From: Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT?

 

Evaluation of NAT with MRI

 

Evaluation of NAT with CT

PD/SD

CR/PR

Total

PD/SD

26

9

35(44.9%)

CR/PR

9

34

43(55.1%)

Total

35(44.9%)

43(55.1%)

78

  1. Abbreviations: NAT Neoadjuvant therapy, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease